There are several relative (promising regarding a reduction in placenta-mediated complications such as
preeclampsia) and absolute (e.g. a recurrent or recent thromboembolic event, mechanical heart valves) reasons for use of
anticoagulant drugs during pregnancy.
Warfarin readily crosses the placenta because of its low molecular weight, and is associated with a distinctive
embryopathy known as fetal
warfarin syndrome when exposure occurs between the sixth and twelfth weeks of gestation.
Warfarin embryopathy may be avoided by stopping
warfarin and switching to
heparin when pregnancy is achieved or as soon as possible after conception. Heparins,
unfractionated heparin and
low molecular weight heparin are the preferred agents for anticoagulation in pregnancy because they show no transplacental passage due to their high molecular weights. Both heparins and
warfarin are safe for the infant during breastfeeding.
Aspirin is prescribed with increasing frequency to reduce the risk of
miscarriage and poor pregnancy outcome. Although
aspirin crosses the placenta, it is safe in low doses. However, the safety of higher doses of
aspirin during the first pregnancy is uncertain.